1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Owen, D. H.; Bunn, P. A.; Johnson, B. E.; Kwiatkowski, D. J.; Kris, M. G.; Wistuba, I. I.; Gandhi, M.; Phan, S.; Shames, D. S.; Schulze, K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Mutational profiling of resected intrahepatic cholangiocarcinoma
    Meeting Abstract

    Pak, L. M.; Goldman, D.; Gonen, M.; Allen, P. J.; Balachandran, V. P.; D'Angelica, M. I.; DeMatteo, R. P.; Kingham, T. P.; Simpson, A.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Bernal, Y.; Halton, E.; Diamonte, C.; Wang, Y.; Brentjens, R. J.; Sadelain, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Mead, E.; Santomasso, B.; Halton, E.; Diamonte, C.; Bernal, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Santomasso, B.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T.; Wang, Y.; Halton, E.; Diamonte, C.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Surgical ovarian ablation for hormone receptor positive primary breast cancer in premenopausal women
    Meeting Abstract

    Oseledchyk, A.; Gemignani, M.; Dickler, M. N.; Goldfarb, S. B.; Iasonos, A.; Zhou, Q.; Carter, J.; Barakat, R. R.; Abu-Rustum, N.; Zivanovic, O.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results
    Meeting Abstract

    O'Reilly, E. M.; Mahalingam, D.; Roach, J. M.; Miller, P. J.; Rosano, M. E.; Krause, S.; Avery, W.; Bekaii-Saab, T. S.; Shao, S. H.; Richards, D. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Dynamics of immune-mediated thyroid dysfunction in patients with advanced renal cell carcinoma receiving checkpoint inhibitor therapy
    Meeting Abstract

    Osorio, J. C.; Patil, S.; Coskey, D. T.; Carlo, M. I.; Feldman, D. R.; Hellmann, M. D.; Voss, M. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)
    Meeting Abstract

    O'Reilly, E. M.; Sahai, V.; Bendell, J. C.; Bullock, A. J.; LoConte, N. K.; Hatoum, H.; Ritch, P. S.; Hool, H.; Leach, J. W.; Sanchez, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Grünwald, V.; Hutson, T. E.; Porta, C.; Powles, T.; Eto, M.; Dutcus, C. E.; Baig, M. A.; Dutta, L.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save